Tag:
PSI-7977
Latest Headlines
Latest Headlines
Gilead shares surge as hep C drug scores a cure for big patient population
Gilead Sciences ( $GILD ) received its first bonus from the monster $10.8 billion deal to acquire Pharmasset ( $VRUS ) after CSO Norbert Bischofberger told analysts yesterday evening that PSI-7977
Bristol bags hot hep C drug developer Inhibitex for $2.5B
Proving once again that hepatitis C is the hottest disease in biotech right now, Bristol-Myers Squibb ( $BMY ) has stepped up to the deal table with a $2.5 billion pact to buy out Inhibitex ( $INHX ), a
Report: How savvy Pharmasset persuaded Gilead to boost its offer by 37%
Bloomberg has gathered at least a few pieces of the puzzle surrounding Gilead Science's ( $GILD ) winning $10.8 billion bid for the red-hot hep C drug developer Pharmasset ( $VRUS ). And anyone
On a roll, Pharmasset outlines 100% cure rate for hot hep C program
Pharmasset is on a roll. The biotech ( $VRUS ) reported yesterday that all 40 hepatitis C patients receiving its closely-watched drug PSI-7977 were essentially cured in the course of the small 12-week
Pharmasset shares continue rise on PhIII plan for interferon-free PSI-7977
Shares of Pharmasset continued their meteoric rise yesterday as investors warmed to the news that the biotech has mapped out its march through the clinic to a new, interferon-free hep C treatment
Pharmasset striding into Ph3 to lead pack of oral Hep C drug developers
Pharmasset ( $VRUS ) has grabbed a leading post in the race for new oral therapies against the hepatitis C virus, initiating a Phase III program involving a combo of its experimental drug PSI-7977 and
Pharmasset surges as it fine tunes hep C drug trial
Pharmasset's PSI-7977 is one of the hottest drugs now in development for hepatitis C. And the biotech burnished its rep this morning by restructuring its clinical program for the treatment, adding
